Press & News

The next generation biopharmaceuticals

Press releases

2022-04-20

NOTICE OF ANNUAL GENERAL MEETING IN AFFIBODY MEDICAL AB (PUBL)

The shareholders of Affibody Medical AB (publ), corporate identity number 556714-5601 (the “Company” or “Affibody”) are hereby invited to attend the annual general meeting of the shareholders on Thursday 19 May 2022, at 1:30 pm CET to be held in company’s premises, Scheeles väg 2, Solna.[read more]

Older press releases

2022-03-07

RallyBio Announces Phase 1 Initiation with RLYB116

Solna, Sweden, March 7, 2022. Affibody’s licensee Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, has announced the initiation of a Phase...[read more]

2022-01-12

Lokon Pharma and Affibody Initiates a Collaboration to Develop Novel Cancer Therapeutics

Uppsala and Solna, Sweden, January 12, 2022. Lokon Pharma AB, a leading biotech company in the area of immunostimulatory gene therapy for cancer delivered by uniquely engineered oncolytic viruses, today announced a collaboration with Affibody AB (“Affibody”) to combine...[read more]

2021-12-14

Affibody AB, ACELYRIN, INC., and Inmagene Announce Positive Interim Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis

Affibody AB, ACELYRIN, INC., and Inmagene Announce Positive Interim Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis SOLNA, Sweden, LOS ANGELES, Calif., and SHANGHAI, China, December 14, 2021 – Affibody AB, ACELYRIN, INC., and...[read more]

Affibodys latest Press releases

2022-06-03

Affibody, ACELYRIN, and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During 2022 European Alliance of Associations for Rheumatology Congress

Data suggest efficacy over standard of care for the treatment of psoriatic arthritis Izokibep was well-tolerated, having a safety...[read more]

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

Interim Report January to March 2020 (May 15, 2020)
Interim Report January to June 2020 (August 21, 2020)
Interim Report January to September 2020 (November 13, 2020)
Year End Report 2020 (February 2021)

Investor information